

SHANGHAI
HEALTH
STUDY

February 23, 2007

Via Electronic and U.S. Mail

Richard Irons, PhD, DABT
Principal Investigator, Shanghai Health Study
University of Colorado Health Sciences Center
4200 East 9th Avenue, C238
Denver, CO 80262

(303) 315-7223 FAX

Re: ***Supplemental Funding for Shanghai Health Study through CinPathoGen***

Dear Dr. Irons:

The Benzene Health Research Consortium (BHRC) wishes to clarify and confirm unanimous support for funding through CinPathoGen, Inc., for the completion of the Shanghai Health Study, as discussed in the February 22, 2007, letter entitled "Supplemental Funding for Shanghai Health Study". This decision was made unanimously by the member company representatives on January 29, 2007.

The Benzene Health Research Consortium (BHRC) wishes to clarify its letter of February 23, 2007. The intent of the words "confirm unanimous support for funding through CinPathoGen, Inc., for the completion of the Shanghai Health Study" was to communicate a vote of the consortium oversight committee members on January 29, 2007. The consortium members understood that actual contracting would be subject to API processes and procedures and agreement with the University of Colorado. It was not the intent of the letter to appear to be making a commitment on behalf of API.

The consortium desires that the study be completed and encourages the timely resolution of and execution of supporting contracts.

Sincerely yours,

Patsy Clegg
Chair, Oversight Committee
Shanghai Health Study

SHANGHAI HEALTH STUDY

cc:

Ralph Altieri - (303) 315-6281 FAX

Charlotte Klaus - (303) 315-6281 FAX

David Ross - (303) 315-0274 FAX

Dan Wilkerson - (303) 315-4446 FAX